NHL and NHLPA nearing agreement on a new CBA that includes 84-game season: reports
The NHL and NHL Players' Association are on the verge of extending the collective bargaining agreement more than a year before it expires and expanding the regular season to 84 games.
The league and union have been in talks since April and are closing in on a memorandum of understanding addressing a number of high-profile topics long before the current agreement runs out in September 2026. The extension that could be announced as soon as Friday at the draft in Los Angeles would provide extended labor peace in a sport that has had multiple work stoppages, including the 2004-05 lockout that wiped out an entire season.
The league and union closing in on a deal was confirmed Thursday by three people familiar with the negotiations who spoke with The Associated Press on condition on anonymity because the deal had not yet been finalized. It was first reported by Daily Faceoff.
Two of the people said the new CBA will increase the regular season to 84 games from 82, shorten the maximum length of contracts and add a playoff salary cap for the first time. Extending the regular season from a total of 1,312 games to 1,344 would also come with curtailing exhibition play.
A salary cap in the postseason would prevent teams from using long-term injured reserve rules to load up their rosters. Currently, teams with players on LTIR can exceed the cap by roughly the amount of the players' salaries until the playoffs begin. The option has been used, for example, by Chicago (Patrick Kane in 2015), Tampa Bay (Nikita Kucherov in 2021) and the Vegas Golden Knights (Mark Stone in multiple seasons) during their playoff runs.
NHL Commissioner Gary Bettman and NHLPA executive director Marty Walsh foreshadowed a quick conclusion to labor talks speaking at the Stanley Cup Final earlier in June. Bettman said the sides were "in really good shape, having really good discussions," and Walsh added that talks were "moving forward, and I feel good with where we are."
A full, new CBA would be the first since 2013. The league and the union have been working on the memorandum negotiated in 2020 to finish that season during the pandemic and would meld that agreement with the framework from 12 years ago.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13 minutes ago
- Globe and Mail
Stock Market News for Jun 27, 2025
U.S. stocks closed higher on Thursday, with the S&P 500 inching closer to a new record high as the ceasefire between Iran and Israel continued to hold, and a batch of economic data gave reasons enough for the Federal Reserve to go for a rate cut. All three major indexes ended in positive territory. How Did The Benchmarks Perform? The Dow Jones Industrial Average (DJI) jumped 0.9%, or 404.41 points, to finish at 43,386.84 points. The S&P 500 rose 0.8%, or 48.86 points, to end at 6,141.02 points and is just a few points away from hitting an all-time high. Communication services, consumer discretionary, materials, and industrials stocks were the biggest gainers. The Consumer Discretionary Select Sector SPDR (XLY) gained 0.9%, while the Communication Services Select Sector SPDR (XLC) and Materials Select Sector SPDR (XLB) added 1.2% and 1.1%, respectively. The Industrials Select Sector SPDR (XLI) added 1%. The Energy Select Sector SPDR (XLE) jumped 1.4%. Nine of the 11 sectors of the benchmark index ended in positive territory. The tech-heavy Nasdaq climbed 1%, or 194.36 points, to close at 20,167.91 points. The fear-gauge CBOE Volatility Index (VIX) was down 1.01% to 16.59. Advancers outnumbered decliners on the NYSE by a 4.76-to-1 ratio. On Nasdaq, a 2.3-to-1 ratio favored advancing issues. A total of 16.22 billion shares were traded on Thursday, lower than the last 20-session average of 18.10 billion. S&P 500 on Track to Hit New Highs Stocks rallied on Thursday after a batch of economic data raised hopes that the Federal Reserve could finally resume rate cuts in the coming weeks. The 90-day pause on liberation-day tariffs ends on July 8. However, White House spokesperson Karoline Leavitt downplayed the trade deal deadlines as, she said, 'The deadline is not critical.' It was also unlikely that President Donald Trump would have implemented those hefty tariffs, which he paused after markets tumbled. Stocks have since made a solid rebound. On Thursday, the S&P 500 closed just a few points away from its all-time intraday high of 6,147.43 points hit in February. The S&P 500 has had a remarkable turnaround, and is up 27% from its intraday low this year, after nearly entering the bear market, triggered by tariff fears in April. The index is now up 4% for the year after overcoming several challenges, including tariffs, inflationary pressures and geopolitical tensions. Tech Stocks Rally The Nasdaq is also on track to hit a new record high. The Nasdaq rally has largely been driven by enthusiasm surrounding artificial intelligence (AI). On Thursday, NVIDIA Corporation ( NVDA ) shares rose another 0.5% after the AI darling's stock hit an all-time high on Wednesday to regain its position as the world's most valuable company. Other tech stocks like Apple, Inc. ( AAPL ) gained 0.3%, while Salesforce, Inc. ( CRM ) rose 1.1%. Apple has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Economic Data Raises Rate Cut Hopes A batch of economic data released on Thursday raised hopes of a rate cut. The final estimate of the GDP showed that the economy shrank 0.5% in the first quarter of 2025, sharply down from the initial estimate of a 0.2% decline. Also, the jobs data released earlier this month hints at a shrinking labor market, which appeared to support the case for the central bank to start rate cuts in the coming weeks. Although Federal Reserve Chairman Jerome Powell said that the central bank is in no hurry to cut interest rates and is ready to wait and watch the inflationary effects of Trump's tariffs on the economy, several other Fed officials have said that a rate cut could come as early as July. Meanwhile, fears of another Wall Street bloodbath owing to the ongoing Middle East crisis have alleviated as the ceasefire between Iran and Israel continues to hold. Economic Data The Labor Department reported that jobless claims totaled 236,000 for the week ending June 21, a decrease of 10,000 from the previous week. The four-week moving average was 245,000, a decrease of 750 from the previous week's revised average of 245,750. Continuing claims came in at 1,974,000, an increase of 37,000 from the previous week's revised level of 1,937,000. The 4-week moving average was 1,941,000, an increase of 16,750 from the previous week's revised average of 1,924,250. The Commerce Department said that durable goods orders soared 16.4% in May after declining 6.6% in April, to record its biggest gain in 11 years. In a separate report, the National Association of Realtors said that pending home sales jumped 1.8% to 72.6 in May, after tumbling by 6.1% to a revised 71.3 in April. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report Salesforce Inc. (CRM): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report
Globe and Mail
18 minutes ago
- Globe and Mail
Chart of the Day 6/27/25: Big Tech is SO Back. Again.
Big Tech is SO back. Again. Ever since the stock market bottomed out on April 7, we've seen most (though not ALL) of the biggest technology stocks rocket higher. All but two are outperforming smaller-capitalization stocks, as represented by the iShares Russell 2000 ETF (IWM), as well as the SPDR S&P 500 ETF Trust (SPY) -- as you can see in this MoneyShow Chart of the Day. 'Big Tech,' SPY, IWM (% Change Since April Low) Nvidia Corp. (NVDA) is the Big Tech name with the most post-"Liberation Day" juice – up 58%. Tesla Inc. (TSLA) isn't far behind, with a 40.4% rally. Next are Microsoft Corp. (MSFT) and Meta Platforms Inc. (META), both nipping at Tesla's heels with gains of 37.8% and 37.3%. Only Apple Inc. (AAPL) and Alphabet Inc. (GOOGL) are notably lagging (+11.2% and +16.4%, respectively). What's behind the resumption of the Big Tech trade – a trade that has periodically popped back up over the past year or two? A few things... First, investors are boosting bets on earlier Federal Reserve rate cuts. Lower rates help boost growth-stock multiples. Second, concerns about tariff and trade policy have eased. President Trump has dialed backed some of his most punitive tariffs – and signaled a willingness to keep negotiating with trade partners. That could prevent some of the worst-case tech supply chain scenarios from playing out. Third, FOMO is back in play. Investors got too bearish during the declines, didn't get on board early enough in the subsequent rally, and they're now dog-piling into old favorites to play catch up. Add it all up and you have a tech sector that is leading again – and driving the averages to new highs. From where I sit, that's bullish…and underscores why my 'Be (Selectively) Bold' approach (still) looks like the right one here. Finally, if you want to get more articles and chart analysis from MoneyShow, subscribe to our Top Pros' Top Picks newsletter here.
Globe and Mail
33 minutes ago
- Globe and Mail
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and Services segment increased 43.2% year over year to $61.9 million, driven by a 58% growth in Insights, the company's data licensing business. Gross profit outpaced revenue growth, up 65.2% with only a modest 3% increase in the cost of revenues. The business has scaled significantly, securing deals with companies like Novartis, Merck EMD, Takeda and United Therapeutics over the past year. Against that backdrop, Tempus' ability to sustain such strong growth rates in Data and Services is particularly impressive. Most of these contracts span multiple years, with total remaining contract value reflecting data and services yet to be delivered. Several recent developments are setting the stage for the momentum to continue. A major highlight is Tempus AI's $200 million data and modeling license agreement with AstraZeneca AZN and Pathos to build the world's largest foundation model, bringing AZN's total remaining contract value to over $1 billion as of April 30. AZN and Pathos are also covering a large portion of the compute costs to train the model. Notably, the agreement's non-exclusive nature allows Tempus to license data and build models with others in the future. The company also expanded its collaboration with Illumina, which will use its multimodal data platform to accelerate clinical benefits of molecular profiling across all major diseases. In May, Tempus inked a large data agreement with Boehringer Ingelheim focused on biomarker development and novel discovery efforts, building on their past collaboration. Further, the company's new oncology-focused platform, Loop, is already in use by a large pharmaceutical company to prioritize drug targets in patient subpopulations with severe unmet needs. TEM's Key Competitors in Data and Services ICON ICLR, an Ireland-based contract research organization, experienced a significant increase in overall biotech opportunities and a modest uptick in project win rates in the first quarter of 2025. However, it was ultimately offset by an increased number of customer-cancelled request for proposal (RFP) opportunities. In large pharma, RFP opportunities were softer in the quarter; still, ICLR's high success rate underscored its strong positioning as a strategic partner. IQVIA 's IQV Technology & Analytics Solutions business continued the strong recovery trend in the first quarter of 2025, with clients launching new drugs and executing their commercial roadmaps. However, IQV faced slower decision-making from clinical customers on new programs, reflecting broader macroeconomic pressure and industry caution. IQVIA reported a 10% increase in average time from RFP issuance to award in the quarter, both year over year and sequentially. TEM Outperforms Peers, Industry, But Valuation Stretched Year to date, Tempus AI shares have surged 102.5%, outperforming the industry's 18% growth and also delivering stronger returns than IQV and ICLR. Image Source: Zacks Investment Research TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.47X compared to the industry average of 5.83X. Image Source: Zacks Investment Research TEM Stock Estimate Trend As you can see, earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture. TEM stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report ICON PLC (ICLR): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report Tempus AI, Inc. (TEM): Free Stock Analysis Report This article originally published on Zacks Investment Research (
